AGTC Genomics

06/12/2025

💜 如果早期癌症筛查能像一次抽血一样简单，会怎样？

对数以百万计的人来说，癌症往往是在出现症状后才被发现——
那时往往已经太迟，生活被彻底改变，甚至让人难以承受。

在 AGTC Genomics，我们相信：
不应等到出现症状，人们才开始掌控自己的健康。

这正是我们研发 CancerScreenDx™ 的原因——
一项正在重塑预防医学未来的突破性技术。

🔬 一次检测。超过 110 种癌症。让行动更早一步。

CancerScreenDx™ 不是一项普通的实验室检测。

它是在疾病尚未成为战斗之前，
为生命点亮的最初希望。

只需简单抽取一管血，这项检测即可筛查超过 110 种癌症信号——
其中包括许多目前 没有常规筛查方式 的癌症。

想象一下，它能改变多少人的命运。
想象无数家庭不再陷入不确定的恐惧中。
想象提前知晓所带来的力量。

💡 为什么这很重要？

因为当癌症在早期被发现时：

✨ 治疗效果显著提升
✨ 存活率大幅上升
✨ 医疗成本与并发症减少
✨ 家庭拥有更多时间
✨ 患者重新掌控人生

CancerScreenDx™ 让这一切成为可能——
无需影像检查、无需内窥镜、无需不适。

只需一次简单抽血，
就能换来一份安心。

🛡️ 值得信赖的科学力量

✔ 可筛查 110+ 种癌症类型
✔ 如果检测到癌症信号，可预测最可能的发病组织
✔ 7–14 个工作日 内即可出具结果
✔ 全程由我们通过 ISO 15189 及美国 CAP（病理医师学院）认证 的基因组学实验室完成
✔ 适用于 40 岁以上人群 或任何希望主动进行健康筛查的人

这不只是未来的癌症筛查方式——
而是当下已经实现的突破。

❤️ 您的健康，值得拥有最强的守护

如果您或您关心的人希望积极预防、领先一步、为未来健康投资——
CancerScreenDx™ 将是一个强而有力的起点。

因为早期筛查不仅仅是医学行为，
它关乎情感，
关乎家庭，
关乎希望。

📩 迈出第一步，从今天开始

无论是个人、诊所、医院或健康管理中心——
我们欢迎合作，将早期筛查带给更多社区。

🌐 www.agtcgenomics.com

📞 +6012-520 7981
📧 info@agtcgenomics.com

早筛查，救生命。
CancerScreenDx™ 为此而生。

06/12/2025

💜 𝐖𝐡𝐚𝐭 𝐢𝐟 𝐞𝐚𝐫𝐥𝐲 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐰𝐚𝐬 𝐚𝐬 𝐬𝐢𝐦𝐩𝐥𝐞 𝐚𝐬 𝐚 𝐬𝐢𝐧𝐠𝐥𝐞 𝐛𝐥𝐨𝐨𝐝 𝐭𝐞𝐬𝐭?

For millions of people, cancer is discovered only when symptoms appear — often too late, often life-changing, often overwhelming.

At AGTC Genomics, we believe no one should have to wait for symptoms before taking control of their health.

That’s why we created CancerScreenDx™, a breakthrough that is reshaping what preventive healthcare can look like.

🔬 𝐎𝐧𝐞 𝐭𝐞𝐬𝐭. 𝐎𝐯𝐞𝐫 110 𝐜𝐚𝐧𝐜𝐞𝐫𝐬. 𝐀 𝐜𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐚𝐜𝐭 𝐞𝐚𝐫𝐥𝐲.

CancerScreenDx™ is not just a laboratory test.

It is hope in the earliest chapter, before cancer becomes a battle.

With a simple blood draw, this test can detect signals from more than 110 cancer types — including many that have no routine screening method today.

Imagine the lives that could change.
Imagine the families spared from uncertainty.
Imagine the power of knowing early.

💡 𝐖𝐡𝐲 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬
Because when cancer is found early:
✨ Treatment is more effective
✨ Survival rates rise dramatically
✨ Costs and complications decrease
✨ Families get more time
✨ Patients get back control

CancerScreenDx™ helps make this possible — with no scans, no scopes, no discomfort.

Just a simple blood test.
Just peace of mind.

🛡️ 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐭𝐫𝐮𝐬𝐭

✔ Detects 110+ cancer types

✔ Predicts the likely tissue of origin when a signal is detected

✔ Results in 7–14 working days

✔ Performed entirely in our ISO 15189 and US College of American Pathologists (CAP)-certified genomics laboratory

✔ Suitable for individuals aged 40+ or anyone seeking proactive health screening

This isn’t the future of cancer detection.

This is now.

❤️ 𝐘𝐨𝐮𝐫 𝐡𝐞𝐚𝐥𝐭𝐡 𝐝𝐞𝐬𝐞𝐫𝐯𝐞𝐬 𝐞𝐯𝐞𝐫𝐲 𝐚𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞
If you or someone you care about wants to be proactive, to stay ahead, to invest in years of wellbeing — CancerScreenDx™ is a powerful starting point.

Because early detection isn’t just medical.

It’s emotional.
It’s personal.
It’s hope.

📩 𝐓𝐚𝐤𝐞 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐬𝐭𝐞𝐩 𝐭𝐨𝐝𝐚𝐲

For individuals, clinics, hospitals, and wellness centers — we welcome collaborations to bring early detection to more communities.

🌐 www.agtcgenomics.com
📞 +6012-520 7981
📧 info@agtcgenomics.com

Early detection saves lives.
CancerScreenDx™ helps make it possible.

05/12/2025

𝐌𝐚𝐥𝐚𝐲𝐬𝐢𝐚’𝐬 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡: 𝐀𝐆𝐓𝐂 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 𝐂𝐀𝐏, 𝐈𝐒𝐎15189 & 𝐈𝐒𝐎17025 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞

We are proud to announce that AGTC Genomics has officially received full accreditation from the College of American Pathologists (CAP) — the gold standard for laboratory quality and precision worldwide.

With this, AGTC Genomics now holds the rare Triple Accreditation that only a select number of advanced genomics laboratories in the world have achieved:

✅ ISO 15189 – International standard for medical laboratories, ensuring exceptional competence, quality, and reliability in clinical diagnostics.

✅ ISO 17025 – International standard for testing and calibration laboratories, demonstrating technical excellence, rigorous validation, and scientific accuracy.

✅ CAP Accreditation – The highest global benchmark for laboratory performance, data integrity, analytical quality, and patient safety.

𝑾𝒉𝒚 𝒕𝒉𝒊𝒔 𝒎𝒂𝒕𝒕𝒆𝒓𝒔:

Triple accreditation is not merely a certification milestone — it is a global recognition of AGTC Genomics’ scientific rigor, diagnostic excellence, and technological leadership. Only a very small number of genomics labs worldwide meet all three international standards simultaneously, reflecting exceptional competency in both clinical and research-grade genomics.

For Malaysia and the region, this achievement signals:

🌐 A new benchmark for world-class genomic diagnostics

🔒 The highest assurance of quality, accuracy, and data integrity

🧬 AGTC’s readiness to support cutting-edge precision medicine, from oncology to rare diseases and population-scale genomics

🚀 A major leap forward in establishing Malaysia as a regional hub for advanced genomics innovation

This milestone would not have been possible without the dedication of our talented scientific, laboratory, quality management, and operations teams — and the trust of our clinical and research partners.

Thank you for believing in our mission to make precision medicine accessible, reliable, and impactful for every patient.

Onward to even greater breakthroughs in genomic science.

Bioeconomy Corporation
Kementerian Sains, Teknologi dan Inovasi (MOSTI)
MRANTI
KEMENTERIAN KESIHATAN MALAYSIA
Akademi Sains Malaysia

02/12/2025

🧬🚀 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐲 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐬 𝐂𝐀𝐏 𝐚𝐜𝐜𝐫𝐞𝐝𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐠𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐭𝐞𝐬𝐭𝐢𝐧𝐠

AGTC Genomics is proud to announce that our laboratory has been officially accredited by the College of American Pathologists (CAP) — one of the world’s most prestigious and rigorous accreditations for clinical laboratories.

This achievement marks a major milestone for AGTC Genomics, affirming our commitment to the highest international standards of quality, accuracy, and patient safety. CAP accreditation places our facility among an elite group of laboratories globally that have demonstrated excellence in analytical performance, stringent quality management systems, and continuous improvement in clinical diagnostics.

🔍 𝑾𝒉𝒂𝒕 𝑻𝒉𝒊𝒔 𝑴𝒆𝒂𝒏𝒔 𝒇𝒐𝒓 𝑴𝒂𝒍𝒂𝒚𝒔𝒊𝒂 & 𝒕𝒉𝒆 𝑹𝒆𝒈𝒊𝒐𝒏

With CAP accreditation, AGTC Genomics strengthens its position as a regional leader in precision medicine, ensuring that clinicians, hospitals, and partners can rely on internationally validated test accuracy and consistency. This recognition also supports our mission to elevate genomics diagnostics and research capability across Southeast Asia.

📌 𝑺𝒆𝒕𝒕𝒊𝒏𝒈 𝑵𝒆𝒘 𝑺𝒕𝒂𝒏𝒅𝒂𝒓𝒅𝒔 𝒇𝒐𝒓 𝑷𝒓𝒆𝒄𝒊𝒔𝒊𝒐𝒏 𝑴𝒆𝒅𝒊𝒄𝒊𝒏𝒆

CAP accreditation further strengthens AGTC Genomics’ foundation as we continue expanding advanced genomics solutions, integrating AI-driven analytics, and bringing world-class precision medicine to hospitals, clinicians, researchers, and patients.

Congratulations to the team — and thank you to our partners and clients for your trust.

More exciting developments to come. Stay tuned. 🚀🧬

27/11/2025

27/11/2025

📢🚀 𝐒𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧𝐢𝐧𝐠 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐀𝐈𝐌𝐒𝐓 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲

A heartfelt thank you to AIMST University for inviting AGTC Genomics to your campus for an engaging discussion on research collaboration and the transformative power of genomics in scientific discovery.

We were honoured to have our Chief Technology Officer, Dr. Boon Shing Tan, conduct a dedicated training session, sharing valuable insights on advanced genomics technologies, sequencing workflows, and the practical applications of multi-omics data in modern research. His session sparked meaningful conversations and deepened understanding of how genomics can accelerate innovation across biomedical and translational studies.

We truly appreciate the warm hospitality and forward-thinking spirit shown by the AIMST team. The enthusiasm among faculty, researchers, and students further reinforces the importance of academia–industry partnerships in shaping Malaysia’s next generation of scientific leaders.

AGTC Genomics looks forward to exploring exciting joint initiatives and contributing to a stronger, more connected genomics research ecosystem.

27/11/2025

𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐚𝐧𝐝 𝐔𝐓𝐀𝐑 𝐒𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐯𝐞 𝐄𝐟𝐟𝐨𝐫𝐭𝐬 𝐢𝐧 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐄𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧

AGTC Genomics extends its sincere appreciation to Universiti Tunku Abdul Rahman (UTAR) Kampar Campus, particularly the Faculty of Science and the Centre for Biomedical and Nutrition Research, for inviting our research scientists and bioinformatics team to deliver an impactful knowledge-sharing session on The Power of Genomics in Research.

The session, featuring Ms. Hiu Ching Toh Ching (Assistant Lab Manager, AGTC Genomics) and Ms. Xin Yi Chew (Bioinformatician, AGTC Genomics), highlighted how RNA sequencing and computational genomics are accelerating breakthroughs in gene expression studies, biological discovery, and precision medicine. Their presentation provided students and researchers with real-world insights into modern genomic technologies and applications.

The engagement and curiosity demonstrated by UTAR students reinforced the importance of academia–industry collaboration in building Malaysia’s future scientific workforce. Genomics continues to transform biomedical research worldwide, and empowering young scientists with hands-on knowledge is essential for driving the nation’s innovation agenda.

AGTC Genomics is grateful for UTAR’s warm hospitality and strong commitment to nurturing the next generation of researchers. We look forward to exploring more collaborative initiatives in education, research, and capacity-building to advance Malaysia’s genomics ecosystem.

26/11/2025

𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐚𝐧𝐝 𝐍𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐁𝐥𝐨𝐨𝐝 𝐂𝐞𝐧𝐭𝐞𝐫 - 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐓𝐫𝐚𝐧𝐬𝐟𝐮𝐬𝐢𝐨𝐧 & 𝐓𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐟𝐨𝐫 𝐌𝐚𝐥𝐚𝐲𝐬𝐢𝐚𝐧

We were honoured to welcome the Dr. Dr.Mohammad Masrin Md Zahrin, the Director of National Blood Bank Kuala Lumpur (Pusat Darah Negara, PDN), Ministry Of Health, Malaysia (KKM) and his team and his delegation to AGTC Genomics for a strategic visit centred on capacity building and research development.

This engagement was made possible through the support of Bioeconomy Corporation, who facilitated the connection and helped bring together key stakeholders in Malaysia’s biomedical ecosystem.

The National Blood Bank plays a vital role in safeguarding Malaysia’s healthcare system—ensuring safe, high-quality blood supply nationwide, overseeing transfusion safety, and supporting hospitals with continuous quality improvement.

As precision medicine becomes a national priority, advanced genomic technologies such as Next-Generation Sequencing (NGS) and digital PCR (dPCR) are reshaping transfusion and transplant practices. These tools enable:

🔬 High-resolution HLA typing to improve transplant compatibility

🧬 Ultra-sensitive detection of transfusion-transmitted infections (TTIs)

🩸 Screening of genetic and hereditary blood disorders

🧫 NGS-based chimerism and donor-derived cfDNA (dd-cfDNA) monitoring post-transplant

📊 Improved donor–recipient matching for complex transfusion scenarios

⚙️ Stronger national data analytics to optimise blood safety and resource planning

With these innovations, Malaysia is moving steadily towards precision transfusion and transplant medicine, enhancing patient outcomes and strengthening national healthcare resilience.

A sincere thank you to PDN’s leadership team and Bioeconomy Corporation for making this engagement possible.

Stay tuned — exciting collaboration developments are coming soon! 🚀🤝

25/11/2025

🚀 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐚𝐬 𝐚 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐌𝐚𝐧𝐚𝐠𝐞𝐫!

AGTC Genomics is on a mission to transform healthcare with precision medicine – and we need a Business Development Manager to power our growth.

✅ Drive market expansion
✅ Build strategic partnerships
✅ Accelerate the adoption of genomics solutions

Requirement: At least 3 years of experience in Next-Generation Sequencing (NGS).

If you’re passionate about innovation and ready to make an impact, we want to hear from you!

📩 Send your CV to info@agtcgenomics.com

09/11/2025

🎙️ Listen to Professor Dr. Chee-Onn Leong, CEO and Founder of AGTC Genomics, as he shares the latest breakthrough in cancer early detection at the recently concluded NICE 2025.

🌍 In his session, Prof. Dr. Leong highlighted how advances in liquid biopsy and multi-cancer early detection (MCED) are transforming the future of oncology — enabling cancers to be detected earlier, faster, and more accurately than ever before.

🔬 Backed by AGTC Genomics’ cutting-edge sequencing technology and AI-driven analytics, this breakthrough represents a major leap toward accessible precision medicine for everyone — bringing hope for better outcomes and improved quality of life.

💡 As Malaysia’s leading genomics company, AGTC Genomics continues to push the boundaries of science and innovation, supporting the nation’s vision of becoming a regional hub for genomics-driven healthcare.

08/11/2025

𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐍𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 & 𝐂𝐫𝐞𝐚𝐭𝐢𝐯𝐢𝐭𝐲 𝐄𝐜𝐨𝐧𝐨𝐦𝐲 (𝐍𝐈𝐂𝐄) 2025 𝐏𝐚𝐧𝐞𝐥 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧

AGTC Genomics had the privilege of joining the panel discussion at the National Innovation & Creativity Economy (NICE) 2025 — bringing together visionary leaders to shape the future of Precision Medicine in Malaysia and beyond.

Representing AGTC Genomics, our Founder & CEO Prof. Dr. Chee-Onn Leong shared insights on how advanced genomics and affordable whole-genome sequencing are redefining clinical diagnostics, public health, and translational research.

The panel delved into thought-provoking discussions on:

💡 Bridging the gap between cutting-edge genomics and clinical implementation

🧬 Ensuring diagnostic quality through ISO 15189-accredited genomics services

🌏 Expanding access to precision medicine across Asia-Pacific populations

🤝 Collaborating for innovation in pharmacogenomics, microbiome, and oncology

One key takeaway from the session —

“Precision Medicine is not just about sequencing genomes; it’s about transforming data into meaningful action for clinicians, patients, and populations.”

We are proud to be part of Malaysia’s precision medicine movement — aligning science, policy, and innovation toward a healthier future.

A heartfelt thank you to the organisers of NICE 2025, our co-panellists, and everyone who visited our booth to explore AGTC Genomics’ latest initiatives in genomics and multi-omics innovation.